English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

US researchers do not need a second federally approved facility for providing research-grade cannabis, the Drug Enforcement Administration (DEA) has ruled. The decision ends an eight-year bid by Lyle Craker at the University of Massachusetts in Amherst, to grow cannabis for medical research, which was supported by the Multidisciplinary Association for Psychedelic Studies (MAPS). A single laboratory at the University of Mississippi supplies cannabis under a contract with the National Institute of Drug Addiction. Craker, MAPS and others have argued that the current supply of cannabis is of inconsistent quality, difficult to obtain, and that efforts to widen that supply are being stalled for political reasons (see Nature 430, 492; 2004). In 2007, a DEA judge recommended that Craker’s application to set up a second facility should be granted; but the DEA’s final ruling, made on 7 January, said the current supply was adequate.

Plan to grow more cannabis for research turned down